Clinical Trial Update: Methylprednisolone Given by 24-Hour or 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 24-hour or 48-hour methylprednisolone infusion versus tirilazad for acute spinal cord injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)
• tirilazad (tirilazad)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Spinal Cord Injury | Phase 3 | Status: COMPLETED